CAY10462 is the hydrochloride salt of CAY10434 and selective inhibitor of the 20-HETE synthase CYP4A11 exhibiting an IC50 of 8.8 nM when tested in human renal microsomes.4 CAY10434 is nearly 200 times less potent as an inhibitor of 1A, 1C, and 3A CYP450.

ThioLox is a competitive 15-lipoxygenase-1 (15-LOX-1) inhibitor. ThioLox shows anti-inflammatory and neuroprotective properties.

Pomalidomide-piperazine is an active compound that can be used to synthesis the E3 ligand for PROTAC.

BRD-K56819078 is a small-molecule senolytics and significantly decreases senescent cell burden and mRNA expression of senescence-associated genes in the kidneys of aged mices.

RM133-3 is an ionizable lipid for potent functional mRNA delivery in vivo. The LPN formulation RM133-3-21, is found to be roughly 4.5 times more potent than DLin-MC3-DMA.

FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models.

1,2-Distearoyl-sn-glycero-3-phosphorylglycerol is used as a component of a loposomal delivery system that coordinates the release of irinotecan and floxuridine in vivo. It is also used to encapsulate anthracyclines and deliver them to tumors.DSPG has a high transition temperature and has therefore found much use in liposomal drug delivery systems.

BAY-7081 is a Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor with very good aqueous solubility.

CFT1946 is an orally active and selective target ligand for BRAF kinase.

KT-474 is a highly active and selective, orally bioavailable IRAK4 degrader being developed for the treatment of toll-like receptor (TLR)/interleukin-1 receptor (IL-1R)-driven immune-inflammatory diseases.

MK-8189 is a potent, orally active and selective PDE10A inhibitor with a Ki value of 29 pM. MK-8189 can be used in research of schizophrenia.

CEE321 is a potent pan JAK inhibitor in enzyme and cellular assays (IC50 = 54 nM). CEE321 potently inhibited biomarkers relevant to atopic dermatitis.

CZS-241 is a Potent, Selective, and Orally Available Polo- Like Kinase 4 Inhibitor for the Treatment of Chronic Myeloid Leukemia.

AK-2292 is a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia.

BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively.

BAY-805 is a potent and selective USP21 inhibitor. BAY-805 is a non-covalent inhibitor with low nanomolar affinity for USP21 and high selectivity over other DUB targets as well as kinases, proteases, and other common off-targets.

BGB-8035 is a Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase (BTK IC50 = 1.1 nM)for B‑Cell Malignancies and Autoimmune Diseases.

ACT-777991 is an orally active and selective CXCR3 antagonist. ACT-777991 has microsomes and hepatocytes stability across animal models. ACT-777991 inhibits the migration of activated T cells toward CXCL11.

IPG7236 is a CCR8 antagonist that through the modulation of regulatory T-cells and cytotoxic T (CD8+ T) cells, displays anticancer effects. IPG7236 is currently undergoing Phase 1 clinical trials in the treatment of advanced solid tumors.

BAY6096, a potent, selective, and highly water-soluble α2B antagonist with IC50 = 14 nM.

A2A receptor antagonist 1 is an antagonist of both adenosine A2A receptor and A1 receptor with Kis of 4 and 264 nM, respectively.